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Summary
Background:  Ultrasound  transducer  reprocessing  is  required  to  prevent  the  transmis-
sion  of  infections  between  patients.  In  some  regions,  reprocessing  practices  are  not
sufﬁcient  to  achieve  high-level  disinfection  (HLD),  which  can  result  in  contaminated
probes.  Furthermore,  current  manual  HLD  methods  use  toxic  chemicals  and  are
prone  to  operator  error/variability.  The  development  of  automated,  non-toxic  HLD
disinfection  devices  may  reduce  the  risk  of  transmission  and  reduce  safety  risks  for
operators  and  patients.  This  study  investigated  the  disinfection  efﬁcacy  of  a hydro-
gen  peroxide-based,  automated  HLD  device,  the  Trophon® EPR,  against  a  range  of
international  standards.
Methods:  Disinfection  efﬁcacy  was  assessed  in  carrier  and  simulated  use  tests  against
21  different  species  of  bacteria,  fungi  and  viruses.  Carrier  tests  were  performed
by  placing  carriers  throughout  the  disinfection  chamber  and  measuring  the  log
reduction  in  viable  organisms  following  disinfection.  These  tests  were  performed
according  to  Association  of  Analytical  Communities  International  Ofﬁcial  Meth-
ods  and  European  and  ASTM  International  Standards  for  bactericidal,  fungicidal,
mycobactericidal,  sporicidal  and  virucidal  disinfection.  Simulated  use  tests  involv-
ing  the  disinfection  of  six  widely  used  ultrasound  probe  models  were  conducted
according  to  ASTM-E1837-96  using  Mycobacterium  terrae  as  a  test  organism.
Results:  The  device  satisﬁed  criteria  for  HLD  and  sporicidal  disinfection  efﬁcacy
under  all  standards  tested.
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Conclusions:  Automated,  hydrogen  peroxide-based  disinfection  devices  offer  an  alter-
native  to  manual  ultrasound  probe  disinfection  technologies.  Such  devices  reduce  the
nd  can  improve  patient  and  operator  safety  by  preventing
icals.  The  adoption  of  next-generation  disinfection  devices
fection  risk  and  improve  patient  safety.
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
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device evaluated  in  this  paper  uses  a nebulized
mist of  35%  hydrogen  peroxide  to  disinfect  ultra-risks  of  operator  error  a
exposure  to  toxic  chem
may  help  to  decrease  in
©  2013  King  Saud  Bin  Ab
Ltd.  All  rights  reserved.
Introduction
Ultrasound  transducers  are  reusable  medical
devices that  require  appropriate  reprocessing
between  patients  to  prevent  the  transmission  of
infectious  disease.  Medical  devices  can  be  catego-
rized based  on  the  infection  risk  associated  with
their intended  use  according  to  the  Spaulding  classi-
ﬁcation  system  [1,2].  Under  this  system,  ultrasound
transducers  that  contact  broken  skin  or  mucous
membranes are  classiﬁed  as  semi-critical  devices
and are  required  to  undergo  a  minimum  of  high-
level disinfection  (HLD)  between  patients.  HLD  is
generally deﬁned  as  a  complete  elimination  of all
microorganisms  although  small  numbers  of  bacte-
rial spores  may  remain.  HLD  is  therefore  required
for a  range  of  common  ultrasound  procedures
including, among  others,  intracavity  ultrasound,
such as  transvaginal  and  transrectal  ultrasonogra-
phy, and  surface  ultrasound  on  broken  skin  (ulcers
and  wounds).
There  are  two  main  approaches  to  preventing
the transmission  of  infection  between  patients
undergoing such  procedures.  The  ﬁrst  involves  cov-
ering the  ultrasound  transducer  with  a  disposable
physical barrier  (an  ultrasound  transducer  cover
or condom).  The  second  method  involves  manual
cleaning  of  the  transducer  followed  by  chemical
treatment to  disinfect  the  device.  Depending
on local  regulations,  some  combination  of  these
two methods  is  used  to  reprocess  ultrasound
transducers.  However,  recent  studies  have  shown
that current  approaches  are  not  always  adequate.
A number  of  studies  have  examined  transducer
cover or  condom  perforation  and  have  found  that
perforation  is  common  (0.9—9%),  resulting  in  a
signiﬁcant  risk  of  transmission  [3—7].  As  a  result,  it
is mandated  in  the  USA,  Canada  and  Australia  that
intracavity  ultrasound  transducers  be  subjected
to HLD  reprocessing  in  addition  to  the  use  of
ultrasound transducer  covers.  Practices  in  other
regions  are  much  more  variable.  A  recent  UK  study
examined  transvaginal  ultrasound  probe  (TVUSP)
reprocessing  practices  in  68  healthcare  institutions
and  found  that  none  met  standards  for  HLD  and
that reprocessing  techniques  were  inconsistent
s
(
h
across  clinics  [8]. In  addition,  studies  in  Hong  Kong
nd France,  among  other  places,  have  shown  that
ltrasound  transducers  may  still  be  contaminated
ith infectious  agents  following  reprocessing
9—11]. This  carryover  is  largely  attributable  to
eprocessing  techniques  that  are  only  capable  of
ow-level disinfection,  highlighting  the  need  for
lear guidelines  for  transducer  reprocessing.  A
ecent meta-analysis  of  the  infection  risk  posed  by
ransvaginal and  transrectal  ultrasonography  found
hat across  multiple  studies,  TVUSPs  were  contam-
nated  with  pathogenic  bacteria  and  viruses  with
 pooled  prevalence  of  12.9%  and  1%,  respectively,
ollowing reprocessing.  For  patients  undergoing
ransrectal ultrasound  and  guided  biopsy,  there
as a pooled  infection  rate  of  3.1%  [10].
The resistance  to  adopting  HLD  in  those  regions
here it  is  not  mandated  has  been  attributed  to
 number  of  problems,  including  increased  toxicity
residual  chemical  exposure  for  patients  and  work-
lace risks  for  reprocessing  staff),  time-intensive
nd costly  disinfection  procedures  and  the  poten-
ial to  shorten  the  life  of  the  transducer  [11].
hese problems  arise  from  the  manual  nature  of
eprocessing  and  the  use  of  toxic  chemicals  that
re required  due  to  the  sensitive  materials  used
n ultrasound  transducer  construction.  Common
isinfectants include  glutaraldehyde,  aldehydes,
eracetic acid  and  quaternary  ammonium  com-
ounds.  Typically,  such  disinfectants  require  a
engthy  reprocessing  time  involving  soaking  the
ransducer  for  10—20  min  followed  by  washing  to
emove the  disinfectants  before  re-use.  Due  to  the
oxicity of  many  chemicals  used  for  HLD,  reprocess-
ng is  often  conducted  in  a  separate  room,  adding
o the  time  and  cost  demands  of  implementing  such
rocesses  in  the  clinic.
To  address  these  challenges  to  adopting  rou-
ine and  effective  HLD  procedures,  new  automated
eprocessing systems  are  becoming  available.  Theound  transducers  in  an  automated  7 min  cycle
Fig.  1).  The  disinfection  process  results  in  the
ydrogen peroxide  being  broken  down  into  oxygen
nd water,  minimizing  toxicity  and  environmental
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pigure  1  The  ultrasound  transducer  disinfection  device  t
eroxide  to  disinfect  ultrasound  transducers  in  an  autom
mpact  with  the  added  beneﬁt  that  the  device  can
e installed  at  the  point  of  care.  The  efﬁcacy  of
xisting  manual  HLD  reprocessing  techniques  is  well
ocumented  [12,13]. However,  the  efﬁcacy  of  auto-
ated devices  that  use  hydrogen  peroxide  is  less
ell established.  We  set  out  to  evaluate  the  bacte-
icidal,  mycobactericidal,  sporicidal,  fungicidal  and
irucidal efﬁcacy  of  the  device  against  a range  of
nternational  standards  for  HLD.
aterials and methods
o  assess  the  disinfection  efﬁcacy  of  the  device,  a
omprehensive  range  of  microbiological  tests  was
onducted  in  accordance  with  international  stan-
ards for  HLD.  The  range  of  organisms  tested  was
elected  based  on  their  use  as  previously  well-
tudied indicators  for  disinfection  efﬁcacy  and/or
n their  clinical  signiﬁcance.  Appropriate  sample
umbers  were  determined  depending  on  the  partic-
lar standard  tested.  The  standards  against  which
fﬁcacy  was  tested  represent  the  most  widely
ccepted standards  for  disinfection  efﬁcacy  in
orth America,  Europe  and  internationally.
utomated HLD reprocessing device
he  ultrasound  transducer  reprocessing  device
valuated was  the  Trophon® EPR  (Nanosonics  Ltd.,
ustralia)  (Fig.  1).  The  device  was  operated  accord-
ng to  the  manufacturer’s  instructions,  and  testing
as carried  out  using  both  inoculated  carriers  and
noculated  ultrasound  transducers  (simulated  use
ests). Carrier  tests  were  conducted  using  a cus-
omized  carrier  stand  that  placed  carriers  at  various
o
t
f
wd  in  this  study  (Trophon®  EPR).  This  device  uses  hydrogen
 cycle.
patially  representative  points  within  the  cham-
er. All  carrier  and  simulated  use  tests  were  run
sing a  standard  processing  cycle.  Efﬁcacy  testing
as conducted  at  four  testing  centers:  AMS  Lab-
ratories,  Australia  (AMS);  Nanosonics,  Australia
NAN);  Biotech  Germande,  France  (BG);  and  the
nstitute of  Medical  Microbiology  and  Hygiene,
übingen University,  Germany  (TU).  The  device
s currently  available  in  the  USA,  UK,  France,
ermany, Australia  and  New  Zealand.
arrier tests — AOAC Ofﬁcial Methods
actericidal  carrier  tests  were  conducted  according
o AOAC  Ofﬁcial  Methods  991.47,  991.48  and  991.49
gainst Salmonella  choleraesuis, Staphylococcus
ureus and  Pseudomonas  aeruginosa, respectively
14—16].  Methicillin-resistant  S.  aureus  (MRSA)  and
ancomycin-resistant  Enterococcus  (VRE)  strains
ere tested  using  AOAC  Ofﬁcial  Method  991.47.
ycobactericidal tests  were  carried  out  according
o AOAC  Ofﬁcial  Method  965.12  against  Mycobac-
erium terrae  [17]. Fungicidal  tests  were  carried
ut according  to  AOAC  Ofﬁcial  Method  955.17
gainst Trichophyton  mentagrophytes,  and  spori-
idal tests  were  carried  out  according  to  AOAC
fﬁcial Method  966.04  against  Clostridium  sporo-
enes  and  Bacillus  subtilis  [18,19].
Inocula  were  prepared  according  to  the  afore-
entioned AOAC  Ofﬁcial  Methods.  The  organic
hallenge was  initiated  by  5%  horse  serum.  Glass
enicylinders,  porcelain  penicylinders,  suture  loops
r glass  slide  carriers  were  inoculated  as  per
he AOAC  methods,  and  test  carriers  were  trans-
erred  onto  a  customized  stand  (Fig.  2A)  for  testing
ithin the  device.  A  standard  disinfection  cycle  was
156  K.  Vickery  et  al.
Figure  2  Carrier  stage  setups  used  to  test  the  disinfection  efﬁcacy  of  the  ultrasound  transducer  reprocessing  device.
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w(A)  Carrier  stage  used  for  AOAC  tests  loaded  with  a  glass
a  plastic  carrier.
run,  and  the  carriers  were  recovered.  Sporicidal
tests were  subjected  to  an  extended  20  min  dis-
infectant contact  time  according  to  AOAC  966.04.
Post-processing,  carriers  were  transferred  to  the
appropriate  broth  supplemented  with  125  IU/mL
of catalase  to  neutralize  any  residual  hydrogen
peroxide activity.  Samples  were  then  cultured  as
per the  AOAC  methods,  with  results  reported  as
growth  or  no  growth.  Control  samples  were  also
run in  accordance  with  the  AOAC  Ofﬁcial  Methods
to establish  viable  counts  for  the  initial  inoc-
ula.
Carrier tests — EN and ASTM standards
Bactericidal  and  sporicidal  tests  were  carried
out according  to  the  European  standard  EN14561
against S.  aureus,  P.  aeruginosa, Enterococcus
hirae, MRSA,  VRE,  Geobacillus  stearothermophilus
and Clostridium  difﬁcile  [20]. Fungicidal  tests
were carried  out  in  accordance  with  EN14562
against Candida  albicans  and  Aspergillus  niger  [21].
Mycobactericidal  tests  were  carried  out  according
to EN14563  against  Mycobacterium  avium  and  M.
terrae [22].
Inocula  were  prepared  according  to  the  afore-
mentioned European  standards.  The  organic  chal-
lenge substituted  5%  horse  serum  for  5%  BSA.
Carriers were  hard  polymer  plastic  and  were
30 mm  ×  20  mm  ×  2  mm  in  dimension.  Inocula  were
spread onto  a  marked  surface  of  20  × 20  mm  and
allowed to  dry  before  being  loaded  onto  the  cus-
tomized  carrier  stand  (Fig.  2B)  for  transfer  to
the device.  Carriers  were  subjected  to  a stan-
dard disinfection  cycle  and  were  transferred  to  the
appropriate  broth  supplemented  with  125  IU/mL  of
catalase to  neutralize  any  residual  hydrogen  perox-
ide activity.  The  carriers  were  cultured  as  per  the
relevant  standard,  and  the  results  are  expressed  as
the mean  log  reduction  in  viable  organism  count
versus the  control.
w
t
w
pcylinder.  (B)  Carrier  stage  used  for  EN  tests  loaded  with
Virucidal  tests  were  carried  out  according  to
STM-E1053 against  poliovirus  (Type  1),  herpes  sim-
lex virus  (Type  1)  and  hepatitis  A  virus  [23].
iral suspensions  were  prepared  as  per  ASTM-
053 and  were  used  to  inoculate  60  mm  circular
lastic carriers.  Carriers  were  dried  and  then  trans-
erred to  the  customized  carrier  stand.  The  carriers
ere subjected  to  a  standard  disinfection  cycle
nd recovered  with  fetal  bovine  serum  containing
25 IU/mL  catalase  solution  to  neutralize  any  resid-
al hydrogen  peroxide  activity  before  being  applied
o Vero  cells  to  detect  residual  infectivity.  Test
amples were  compared  with  controls  to  achieve
 mean  log  reduction  in  infection-competent  viral
oad. Cytotoxicity  controls  were  also  run  to  ensure
hat any  cell  death  could  be  attributed  to  viral
nfection alone.
imulated use tests
ll  simulated  use  tests  were  carried  out  accord-
ng to  ASTM-E1837-96  using  M.  terrae  as  the  test
rganism  [24].  Ultrasound  transducers  were  dis-
nfected  before  inoculation  by  soaking  in  7.5%
ydrogen  peroxide  solution  for  10  min  followed  by
oaking in  a sterile  solution  of  catalase  (125  IU/mL)
or 10  min  and  ﬁnally  soaking  in  sterile  deionized
ater for  10  min.  Inocula  were  prepared  accord-
ng to  ASTM-E1837-96  using  5%  horse  serum  as  the
rganic  challenge.  Four  20  mm  ×  30  mm  regions  on
he transducer  handle,  body  (one  on  each  side)  and
indow were  inoculated  with  organism  and  were
llowed  to  dry.  Following  drying,  the  inoculated
rea on  the  handle  was  swabbed  to  establish  the
ontrol  count  prior  to  disinfection.  The  transducer
as then  transferred  to  the  disinfection  device  and
as subjected  to  a  standard  reprocessing  cycle.  The
ransducer was  recovered,  and  the  remaining  areas
ere swabbed  and  transferred  to  7H9  broth  sup-
lemented  with  125  IU/mL  catalase  to  inactivate
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Table  1  Carrier  tests  based  on  AOAC  Ofﬁcial  Methods.
Standard  Testing  centera n  (carriers)  Growth  Pass/failb
Bactericidal  —  Glass  penicylinders
S.  aureus  ATCC  6538  AOAC  991.48  NAN  60  1  Pass
P.  aeruginosa  ATCC  15442  AOAC  991.49  NAN  60  0  Pass
S.  choleraesuis  ATCC  10708  AOAC  991.47  NAN  60  1  Pass
MRSA  ATCC  43300  AOAC  991.47  NAN  10  0  Pass
MRSA  ATCC  29247 AOAC  991.47  NAN  10  0  Pass
MRSA  clinical  isolate AOAC  991.47 AMS  10  0  Pass
VRE  ATCC  51299 AOAC  991.47 NAN  10  0  Pass
VRE  clinical  isolate  AOAC  991.47  AMS  10  0  Pass
Mycobactericidal  —  Porcelain  Penicylinders
M.  terrae  ATCC  15775  AOAC  965.12  NAN  40  0  Pass
Sporicidal  —  Porcelain  Penicylinders
C.  sporogenes  ATCC  3584  AOAC  966.04  AMS  180  0  Pass
C.  sporogenes  ATCC  3584  AOAC  966.04  NAN  180  0  Pass
B.  subtilis  ATCC  19659  AOAC  966.04  NAN  180  0  Pass
Sporicidal  —  Suture  Loops
C.  sporogenes  ATCC  3584  AOAC  966.04  AMS  180  0  Pass
C.  sporogenes  ATCC  3584  AOAC  966.04  NAN  180  0  Pass
B.  subtilis  ATCC  19659  AOAC  966.04  AMS  120  0  Pass
B.  subtilis  ATCC  19659  AOAC  966.04  NAN  180  0  Pass
Fungicidal  —  Glass  Slide
T.  mentagrophytes  ATCC  9533  AOAC  955.17  NAN  10  0  Pass
omyc
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TMRSA = Methicillin resistant Staphylococcus aureus;  VRE = Vanc
a AMS = ams Laboratories, Australia; NAN = Nanosonics, Aust
b Based on AOAC criteria.
ny  residual  hydrogen  peroxide.  The  solutions  were
hen cultured  according  to  ASTM-E1837-96,  and  the
esults are  reported  as  the  mean  log  reduction  in
iable organism  count  over  the  control  across  the
hree inoculation  sites.
esults
arrier tests — AOAC Ofﬁcial Methods
he  carrier  test  results  of  the  tests  performed
ccording  to  the  AOAC  Ofﬁcial  Methods  are  pre-
ented  in  Table  1.  All  controls  were  within  normal
anges, and  all  samples  tested  passed  the  efﬁcacy
ut-offs  set  by  the  relevant  AOAC  Ofﬁcial  Meth-
ds for  HLD.  Based  on  these  results,  the  device
s capable  of  HLD  under  the  AOAC  Ofﬁcial  Meth-
ds.  Additionally,  the  device  satisﬁes  the  criteria
or sporicidal  claims  with  an  extended  20  min  disin-
ectant  contact  time.
arrier tests — EN and ASTM standardsable  2  shows  the  results  of  the  carrier  tests  per-
ormed  according  to  the  European  and  ASTM  stan-
ards.  The  mean  log  reduction  in  viable  organism
t
u
d
uin resistant Enterococcus.
oad  after  disinfection  and  the  standard  error  of  the
ean (SEM)  were  calculated  for  each  of  the  carrier
est cycles.  All  controls  were  within  normal  ranges,
nd all  samples  tested  passed  the  efﬁcacy  cut-offs.
hese  data  indicate  that  the  device  satisﬁes  the
riteria for  HLD  under  both  EN  and  ASTM  standards.
imulated use tests
he  results  of  tests  simulating  worst-case  condi-
ions under  ASTM-E1837-96  are  shown  in  Table  3.
he mean  log  reduction  in  viable  organism  count
nd the  SEM  were  calculated  for  each  simulated  use
est. The  mycobacterial  load  was  reduced  by  more
han 6 log  in  all  cases.  These  results  indicate  that
he device  is  capable  of  HLD  under  the  simulated
se conditions.
iscussion
he  efﬁcacy  results  showed  that  the  device  consis-
ently  achieved  HLD  in  both  carrier  and  simulated
se tests  using  typical  intracavity  ultrasound  trans-
ucers. Aspects  of  the  testing  methodologies
sed were  more  challenging  than  would  likely  be
158  K.  Vickery  et  al.
Table  2  Carrier  tests  based  on  EN  and  ASTM  standards.
Standard  Testing
centera
n
(cycles)
Mean  log
reduction
SEM  Pass/failb
Bactericidal
S.  aureus  ATCC  6538  EN14561  AMS  12  6.92  0.09  Pass
S.  aureus  ATCC  6538  EN14561  NAN  6  7.40  0.00  Pass
S.  aureus  ATCC  6538 EN14561  TU  5  6.68  0.12  Pass
S.  aureus  CIP  4.83 EN14561  BG  3  6.40  0.06  Pass
P.  aeruginosa  ATCC  15442 EN14561  AMS  6  6.10 0.04 Pass
P.  aeruginosa  ATCC  15442  EN14561  NAN  6  6.25  0.02  Pass
P.  aeruginosa  ATCC  15442  EN14561  TU  5  6.79  0.02  Pass
E.  hirae  ATCC  10541  EN14561  AMS  6  6.67  0.28  Pass
E.  hirae  ATCC  10541  EN14561  NAN  6  7.00  0.22  Pass
E.  hirae  ATCC  10541  EN14561  TU  5  6.63  0.10  Pass
MRSA  ATCC  43300  EN14561  NAN  3  6.97  0.00  Pass
MRSA  ATCC  29247  EN14561  NAN  3  6.80  0.00  Pass
VRE  ATCC  51299  EN14561  NAN  3  6.15  0.00  Pass
Mycobactericidal
M.  avium  ATCC  15769  EN14563  AMS  6  7.25  0.02  Pass
M.  avium  ATCC  15769  EN14563  NAN  6  6.85  0.02  Pass
M.  avium  ATCC  15769  EN14563  TU  5  6.52  0.00  Pass
M.  terrae  ATCC  15775  EN14563  AMS  12  7.13  0.01  Pass
M.  terrae  ATCC  15775  EN14563  NAN  6  6.55  0.02  Pass
M.  terrae  ATCC  15775  EN14563  TU  5  6.02  0.28  Pass
M.  terrae  CIP  104321  EN14563  BG  3  6.07  0.03  Pass
Sporicidal
G.  stearothermophilus  ATCC  7953  EN14561  AMS  6  6.75  0.34  Pass
G.  stearothermophilus  ATCC  7953  EN14561  NAN  6  6.10  0.04  Pass
G.  stearothermophilus  ATCC  7953  EN14561  BG  3  6.23  0.07  Pass
C.  difﬁcile  ATCC  43593  EN14561  NAN  3  6.23  0.05  Pass
Fungicidal
C.  albicans  ATCC  10231  EN14562  AMS  6  5.48  0.22  Pass
C.  albicans  ATCC  10231  EN14562  NAN  6  5.38  0.15  Pass
A.  niger  ATCC  16404  EN14562  AMS  6  5.47  0.22  Pass
A.  niger  ATCC  16404  EN14562  NAN  6  6.28  0.24  Pass
A.  niger  IP  1431.83 EN14562  BG  3  5.93  0.03  Pass
Virucidal
Polio  Virus  Type  1  (ATCC  VR-192)  ASTM  E  1053-11  AMS  7  4.29  0.20  Pass
Polio  Virus  Type  1  (ATCC  VR-192)  ASTM  E  1053-11  NAN  10  4.18  0.05  Pass
Polio  Virus  Type  1  (ATCC  VR-192)  ASTM  E  1053-11  BG  4  4.28  0.05  Pass
Herpes  Simplex  Virus  Type  1  ATCC  VR-733  ASTM  E  1053-11  AMS  6  3.85  0.29  Passc
Herpes  Simplex  Virus  Type  1  ATCC  VR-733  ASTM  E  1053-11  NAN  4  4.00  0.00  Pass
Hepatitis  A  Virus  ATCC  CRL-1688  ASTM  E  1053-11  AMS  2  4.35  0.15  Pass
MRSA = Methicillin-resistant Staphylococcus aureus; VRE = Vancomycin-resistant Enterococcus; SEM = Standard error of the mean.
a AMS = ams Laboratories, Australia; NAN = Nanosonics, Australia; BG = Biotech Germande, France; TU = Tübingen University,
Germany.
a
t
u
tb Based on EN or ASTM criteria.
c Cytotoxicity >2; >3 log reduction required for pass.
encountered  in  real-world  disinfection  practices.
All penicylinder  tests  incorporated  the  presence  of
mated surfaces  where  the  penicylinders  contacted
the carrier  stand.  Such  contact  points  are  difﬁ-
cult to  disinfect  and  are  the  likely  cause  of  the
low levels  of  breakthrough  growth  of  S.  aureus  and
S. choleraesuis  (however,  the  results  still  met  the
b
r
Bcceptance  criteria  for  HLD)  (Table  1).  To  increase
he realism  of  the  tests,  appropriate  materials  were
sed where  possible.  All  tests  performed  according
o EN  standards  used  plastic  carriers  (acrylonitrile
utadiene styrene)  that  are  typical  of  those  mate-
ials used  in  ultrasound  transducer  construction.
ased on  the  broad  efﬁcacy  observed  under  the
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Table  3  Simulated  use  tests  on  a  range  of  widely  used  transvaginal  ultrasound  transducers.
Manufacturer  Ultrasound  transducer
model
Testing
centera
n  (transducers)  Mean  log
reduction
SEM  Pass/failb
ATL  Linear  Array  L11-5  AMS  4  7.14  0.12  Pass
ATL  Linear  Array  L11-5  NAN  2  6.99  0.21  Pass
GE  3.5C  NAN  1  7.13  N/A  Pass
Acuson  C3  AMS  2  7.35  0.05  Pass
GE  618E,  Model:  2197484  AMS  2  7.20  0.10  Pass
ATL Curved  Array  C9-5  ICT AMS  2  6.80  0.20  Pass
Medison  L3  probe AMS  2  6.91 0.04  Pass
SEM = Standard error of the mean.
a AMS = ams Laboratories, Australia; NAN = Nanosonics, Australia.
b Based on ASTM-E1837-96 criteria.
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iange  of tests  conducted,  the  device  offers  an  alter-
ative  to  users  of  traditional  manual  disinfection
olutions.
The testing  of  large  numbers  of  replicate  sam-
les across  multiple  testing  centers  allowed  for
he analysis  of  the  consistency  of  the  disinfection
fﬁcacy. The  SEM  for  both  AOAC  Ofﬁcial  Methods
nd simulated  use  tests  was  low  (less  than  0.4  log
eductions  in  viable  count  across  all  samples),  indi-
ating that  the  device  tested  is  able  to  achieve  HLD
ith a  low  degree  of  variability.  Such  consistency
ay offer  advantages  over  manual  HLD  reprocess-
ng methods,  which  may  provide  more  opportunities
or operator  error  or  variation.  During  a  study  on
he human  papilloma  virus  (HPV)  contamination  of
VUSPs in  Hong  Kong,  researchers  noted  that  the
roportion  of  HPV-positive  transducers  dropped  off
ver the  course  of  the  study  [9]. Importantly,  the
uthors  attributed  this  improvement  in  disinfection
fﬁcacy to  the  staff  becoming  aware  of  the  study
nd therefore  changing  their  behavior  and  being
ore stringent  in  performing  the  disinfection  pro-
edure.  Such  human  variation  is  not  unexpected,
nd some  regulatory  agencies  have  set  guidelines
hat give  preference  to  reprocessing  techniques
hat are  performed  in  an  automated  fashion.  The
ommission  for  Hospital  Hygiene  and  Infection  Pre-
ention in  Germany  recommends  that  automated
ethods for  reprocessing  medical  devices  be  used
here possible  [25]. Similarly,  UK  guidelines  set  out
y the  Department  of  Health  recommend  that  the
anual reprocessing  of  medical  devices  should  be
estricted  to  those  items  that  cannot  be  processed
n an  automated  manner  [26].
The experiments  presented  herein  all  involved
ab-based testing  with  heavy  inocula  and  organic
oiling  in  an  effort  to  represent  worst-case  scenar-
os in  clinical  practice.  Although  these  lab-based
ests are  widely  accepted  as  evidence  of  efﬁcacy,
E
Nlinical  studies  that  examine  performance  in  a real-
orld setting  would  be  desirable  to  fully  investigate
fﬁcacy. Such  clinical  investigations  will  be  the  sub-
ect of  future  work.
In  conclusion,  automated  devices  that  utilize
ydrogen peroxide-based  disinfection  technology
ffer advantages  to  users  and  patients.  Hydro-
en peroxide  offers  a  less  toxic  alternative
o glutaraldehyde-based  disinfection  technologies,
nd automation  reduces  the  chance  of  operator
ariability in  reprocessing.  The  results  from  this
tudy show  that  automated,  hydrogen  peroxide-
ased reprocessing  devices  can  achieve  HLD  of
ltrasound  probes  in  both  carrier  and  simulated-
se tests.  Given  the  safety  beneﬁts  to  operators
nd patients,  such  devices  will  likely  become  more
idely  used  in  the  future.
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